Social Deprivation and Pregnancy

NCT ID: NCT03121196

Last Updated: 2017-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

615 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-31

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Social deprivation during pregnancy is associated to adverse perinatal outcomes. However, prenatal screening of social deprivation by reliable measurement is not performed. Prevalence of social deprivation is yet underestimated during pregnancy and vulnerable women are not being provided optimal prenatal care.

Our aim is to validate EPICES score during pregnancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The process of deprivation was defined first by J. Wrezinski and P. Townsend who also reported that deprivation is the main cause of inequalities in health. Several studies have already shown an association between socioeconomic deprivation and adverse birth outcomes. EPICES score is the only one that measure individual deprivation. The EPICES score should be therefore included systematically in standard follow-up of pregnant women.

Descriptive analysis will assess women's characteristics and prevalence of social deprivation. Two groups of women will be compared deprived women and non-deprived women.

Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gestational Diabetes High Blood Pressure Prematurity Fetal Growth Restriction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

deprived women

Two groups of women will be compared deprived women and non-deprived women

Epices score

Intervention Type OTHER

Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression

non-deprived women

Two groups of women will be compared deprived women and non-deprived women

Epices score

Intervention Type OTHER

Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Epices score

Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* more than 18 years old
* delivery at 2 maternity hospitals of Clermont-Ferrand area
* fluent command of spoken and written French

Exclusion Criteria

* Terminations of pregnancy
* protected women
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Françoise VENDITELLI

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Patrick LACARIN

Role: CONTACT

04 73 75 11 95

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Patrick LACARIN

Role: primary

04 73 75 11 95

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-A02076-45

Identifier Type: OTHER

Identifier Source: secondary_id

CHU-319

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.